Palvella Therapeutics (NASDAQ:PVLA) Hits New 12-Month High – What’s Next?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) hit a new 52-week high on Wednesday. The company traded as high as $162.31 and last traded at $162.51, with a volume of 132,908 shares. The stock had previously closed at $152.93.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Truist Financial set a $207.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Chardan Capital reissued a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, October 28th. Finally, HC Wainwright restated a “buy” rating on shares of Palvella Therapeutics in a research note on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $209.79.

Palvella Therapeutics Stock Performance

The company’s 50 day moving average price is $141.70 and its 200-day moving average price is $127.15. The company has a market cap of $2.31 billion, a PE ratio of -33.35 and a beta of -0.21.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). Equities research analysts expect that Palvella Therapeutics, Inc. will post -6.39 EPS for the current year.

Insider Buying and Selling at Palvella Therapeutics

In other news, Director George M. Jenkins sold 7,174 shares of the stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the transaction, the director owned 139,790 shares in the company, valued at approximately $18,223,024.40. This represents a 4.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the sale, the director directly owned 250 shares of the company’s stock, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 61,056 shares of company stock worth $8,756,946 over the last ninety days. 17.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in shares of Palvella Therapeutics by 25.4% during the first quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock worth $4,733,000 after acquiring an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Palvella Therapeutics by 688.9% in the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock worth $2,232,000 after acquiring an additional 15,637 shares during the period. Blue Owl Capital Holdings LP bought a new position in shares of Palvella Therapeutics in the second quarter worth $5,541,000. Deutsche Bank AG purchased a new position in shares of Palvella Therapeutics in the second quarter valued at $1,809,000. Finally, WCM Investment Management LLC purchased a new position in shares of Palvella Therapeutics in the first quarter valued at $4,982,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.